07-01-2021
Tada Images / Shutterstock.com
Pharmaceutical companies MSD (known as 'Merck & Co' in the US) and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia (ezetimibe) should be reversed because the circumstances of the class members do not justify an award of class status.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
MSD, Glenmark, generic competition, pay-for-delay, Zetia, cholesterol drug, ezetimibe, class certification, settlement, wholesalers, patent infringement
Virginia judge says court should deny class cert in Zetia antitrust suit
27-01-2022
Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case
04-11-2021
Buyers of Zetia seek class recertification after 4th circ ruling
28-09-2021
Glenmark becomes fifth generic to be charged with US antitrust violations
02-07-2020
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
10-03-2020
